Spinal cord injury is accompanied by a substantial loss of neurons.Cell replacement therapy improves motor and sensory dysfunction by replacing dead neurons,and endogenous neurogenesis is an important cell replacement...Spinal cord injury is accompanied by a substantial loss of neurons.Cell replacement therapy improves motor and sensory dysfunction by replacing dead neurons,and endogenous neurogenesis is an important cell replacement source.Stimulating endogenous neurogenesis is therefore a viable approach for treating spinal cord injury.Given that basic fibroblast growth factor is a potent inducer of neurogenesis,we developed a sustained-release system of basic fibroblast growth factor-chitosan to enhance tissue repair in spinal cord injury.In the present study,we isolated neural stem cells from the spinal cords of neonatal rats and used single-cell RNA sequencing to trace the complete process of neurogenesis under ex vivo culture conditions.Under the influence of basic fibroblast growth factor-chitosan,neural stem cells were able to transition from a quiescent state to an activated state and subsequently differentiate into neuronal precursor cells and immature neurons.Additionally,basic fibroblast growth factor-chitosan significantly enhanced neural stem cell proliferation in vitro and promoted neuronal generation.Subsequent in vivo experiments confirmed the therapeutic efficacy of basic fibroblast growth factor-chitosan in spinal cord injury,demonstrating enhanced neurogenesis and tissue repair.展开更多
background The 1-month case fatality of ischaemic stroke is an essential epidemiological metric.Whereas the case fatality after ischaemic stroke and the temporal trend is uncertain.We aimed to estimate the 1-month cas...background The 1-month case fatality of ischaemic stroke is an essential epidemiological metric.Whereas the case fatality after ischaemic stroke and the temporal trend is uncertain.We aimed to estimate the 1-month case fatality of ischaemic stroke and its temporal trend,as well as its regional variation.Methods We searched PubMed and Embase to identify the studies for 1-month case fatality of ischaemic stroke.The population-based studies were included.Two investigators extracted the data and assessed the quality independently.One-month case fatality of ischaemic stroke was estimated using a random effects model.The temporal trend was evaluated using a mixed-effect meta-regression model.results A total of 59 articles with 77 time periods were included.The worldwide 1-month case fatality of ischaemic stroke was 13.5%(95%CI 12.3%to 14.7%).The case fatality was 10.8%(95%CI 8.3%to 13.5%)in Asia,14.2%(95%CI 12.6%to 15.9%)in Europe,14.0%(95%CI 11.2%to 17.1%)in South America and Caribbean,14.0%(95%CI 9.5%to 19.1%)in North America and 12.5%(95%CI 11.1%to 13.9%)in Australia and New Zealand.Overall,there was a non-significant decrease of 0.1%per year in case fatality.It decreased significantly in Europe(−0.2%annually,95%CI−0.4%to−0.01%)and North America(−0.2%annually,95%CI−0.4%to−0.04%),increased significantly in Australia and New Zealand(0.2%annually,95%CI 0.1%to 0.4%),while no evidence of change in other regions.Conclusion The 1-month case fatality of ischaemic stroke and its temporal trend were divergent across regions.Further studies are needed to address the reason of the regional difference,which will be helpful to guide the effort of reducing stroke burden.展开更多
基金supported by the National Natural Science Foundation of China,Nos.82271403(to XL),82272171(to ZY),31730030(to XL),81941011(to XL),31971279(to ZY)the Natural Science Foundation of Beijing,No.7222004(to HD).
文摘Spinal cord injury is accompanied by a substantial loss of neurons.Cell replacement therapy improves motor and sensory dysfunction by replacing dead neurons,and endogenous neurogenesis is an important cell replacement source.Stimulating endogenous neurogenesis is therefore a viable approach for treating spinal cord injury.Given that basic fibroblast growth factor is a potent inducer of neurogenesis,we developed a sustained-release system of basic fibroblast growth factor-chitosan to enhance tissue repair in spinal cord injury.In the present study,we isolated neural stem cells from the spinal cords of neonatal rats and used single-cell RNA sequencing to trace the complete process of neurogenesis under ex vivo culture conditions.Under the influence of basic fibroblast growth factor-chitosan,neural stem cells were able to transition from a quiescent state to an activated state and subsequently differentiate into neuronal precursor cells and immature neurons.Additionally,basic fibroblast growth factor-chitosan significantly enhanced neural stem cell proliferation in vitro and promoted neuronal generation.Subsequent in vivo experiments confirmed the therapeutic efficacy of basic fibroblast growth factor-chitosan in spinal cord injury,demonstrating enhanced neurogenesis and tissue repair.
基金supported by the Ministry of Science and Technology of the People’s Republic of China(2017YFC1307702)Capital’s Funds for Health Improvement and Research(2020-1-2041)Beijing Municipal Administration of Hospitals’Sail Plan(XMLX201712).
文摘background The 1-month case fatality of ischaemic stroke is an essential epidemiological metric.Whereas the case fatality after ischaemic stroke and the temporal trend is uncertain.We aimed to estimate the 1-month case fatality of ischaemic stroke and its temporal trend,as well as its regional variation.Methods We searched PubMed and Embase to identify the studies for 1-month case fatality of ischaemic stroke.The population-based studies were included.Two investigators extracted the data and assessed the quality independently.One-month case fatality of ischaemic stroke was estimated using a random effects model.The temporal trend was evaluated using a mixed-effect meta-regression model.results A total of 59 articles with 77 time periods were included.The worldwide 1-month case fatality of ischaemic stroke was 13.5%(95%CI 12.3%to 14.7%).The case fatality was 10.8%(95%CI 8.3%to 13.5%)in Asia,14.2%(95%CI 12.6%to 15.9%)in Europe,14.0%(95%CI 11.2%to 17.1%)in South America and Caribbean,14.0%(95%CI 9.5%to 19.1%)in North America and 12.5%(95%CI 11.1%to 13.9%)in Australia and New Zealand.Overall,there was a non-significant decrease of 0.1%per year in case fatality.It decreased significantly in Europe(−0.2%annually,95%CI−0.4%to−0.01%)and North America(−0.2%annually,95%CI−0.4%to−0.04%),increased significantly in Australia and New Zealand(0.2%annually,95%CI 0.1%to 0.4%),while no evidence of change in other regions.Conclusion The 1-month case fatality of ischaemic stroke and its temporal trend were divergent across regions.Further studies are needed to address the reason of the regional difference,which will be helpful to guide the effort of reducing stroke burden.
